IK Investment Partners to sell Colosseum Smile to Jacobs Holding AG


IK Investment Partners to sell Colosseum Smile to Jacobs Holding AG

IK Investment Partners (“IK”) is pleased to announce that the IK 2007 Fund has reached an agreement to sell Colosseum Smile Group, leading provider of private dental care in Scandinavia, to Jacobs Holding AG (“JAG”). Financial terms of the transaction are not disclosed.

Colosseum Smile Group was acquired by IK in 2010 and has since then accelerated its growth and consolidation of the Scandinavian dentistry market. Today Colosseum Smile is the leading provider of private dental care in Scandinavia with 52 clinics in Norway, Sweden and Denmark, offering a range of services from basic dental care to specialist surgery.

“Together with our employees and supported by IK, we have successfully developed Colosseum Smile from two smaller dentist chains to a high quality private dental care provider. We believe we have now reached a phase when we, together with JAG, will be able to take the next step in our development to reach our mission to be the best and most recognised Scandinavian provider of modern dental care for both customers and producers,” said David Halldén, CEO of Colosseum Smile.

Headquartered in Oslo, Colosseum Smile offers a full range of dental care services through its state of the art clinics across Scandinavia. The group has more than tripled in size since IK acquired Colosseum in Norway 2010 and merged Colosseum and Smile in Sweden in 2014.

Colosseum Smile has taken an active role in consolidating the fragmented dental care markets in Norway, Sweden and Denmark. Today the group’s sales amount to over 1.2 billion NOK.

”With numerous acquisitions and a merger, and together with Colosseum Smile’s management team, we have successfully transformed the company from an entrepreneurial endeavor to a leading chain in Scandinavia. The company is a first mover to integrate and consolidate the Scandinavian market, and is now ready to further leverage its platform,” said Thomas Klitbo, Partner at IK Investment Partners and advisor to the IK 2007 Fund.

“We are looking forward to acquire Colosseum Smile Group with its strong track record of delivering high quality care and offering excellent value to its patients and producers alike. We are excited to partner with the management team, and support them in their continuous efforts of building the leading dentistry chain in the Nordics,” said Tomas Aubell, Head of Investments at JAG.

The transaction is expected to close in the beginning of 2017.

For further questions, please contact:

Colosseum Smile
David Halldén, CEO
Phone: +46 708 441998

IK Investment Partners
Thomas Klitbo, Partner
Phone: +44 207 304 4300

Mikaela Hedborg
Communications & ESG Manager
Phone: +44 77 87 573 566

About Colosseum Smile
Colosseum Smile is Scandinavia’s largest private dental chain with 52 clinics in Norway, Sweden and Denmark. The group has more than 1,200 employees. W e are a dental chain with general dentists, dental hygienists, dental assistants and 90 leading specialists in all dental areas – all with the ambition to offer the best Nordic dentistry. Involvement, Innovative thinking and a holistic perspective form the cornerstones of Colosseum Smile’s values and guides us in how we conduct dental treatment and our aspiration to be the industry’s best workplace. For more information, please visit www.smile.se and www.colosseumklinikken.no

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €9 billion of capital and invested in over 100 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

About Jacobs Holding AG
JAG is a global professional investment firm based in Zurich and founded in 1994 by entrepreneur Klaus J. Jacobs. Its sole economic beneficiary is the Jacobs Foundation, one of the world’s leading charitable foundations dedicated to child and youth development. JAG has an established track record of holding its investment for long periods with the aim to successfully compete and become global market leaders in their respective fields. Previous and current investments include Jacobs Suchard AG, Adecco Group AG and Barry Callebaut AG. For more information, visit www.jacobsag.ch

Categories: News


Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma and Consumer Healthcare Industries

Strategic Advantages

  • Lonza to acquire Capsugel for USD 5.5 billion, including refinancing of existing Capsugel debt of USD ~2 billion
  • Acquisition is expected to accelerate Lonza’s growth and ability to deliver value along the healthcare continuum
  • Acquisition addresses needs of customers for integrated, value-added solutions that accelerate drug and ingredient delivery to patients and consumers
  • The combined portfolio offering will position Lonza as the development, formulation, delivery technology and manufacturing partner of choice for the pharma industry
  • Lonza will become a fully integrated solutions provider in oral delivery technologies and active ingredients to the consumer healthcare and nutrition markets

Financial Advantages

  • Lonza expects to achieve CHF ~30 million p.a. operating synergies and CHF ~15 million tax synergies p.a. by year three and CHF ~100 million p.a. top-line synergies in the mid- to long-term
  • Transaction is expected to be CORE EPS accretive in the first full year post closing
  • Capsugel’s profitable business model and robust cash generation expected to further enhance Lonza’s strong financial profile
  • Lonza intends to retain current dividend policy and maintain ~3x net debt/EBITDA leverage

Lonza Group AG (“Lonza,” VTX: LONN.VX), KKR and Capsugel S.A. (“Capsugel”) today announced that they have entered into a definitive agreement under which Lonza will acquire Capsugel from KKR for USD 5.5 billion in cash, including refinancing of existing Capsugel debt of approximately USD 2 billion, through a transaction that has been approved by the Boards of Directors of both Lonza and Capsugel. The transaction will be financed with a combination of debt and equity financing. The EV/adjusted EBITDA multiple for the transaction adds up to 15.1x based on the last 12 months adjusted EBITDA figures up to September 2016.

This acquisition is fully in line with Lonza’s stated strategy to accelerate growth and deliver value along the healthcare continuum by complementing its existing offerings and by opening up new market opportunities in the pharma and consumer healthcare and nutrition industries. With the acquisition of Capsugel, Lonza will add a trusted brand with a large breadth of technologies and will expand the market reach of its contract development and manufacturing organization (CDMO) and products businesses. It will also support Lonza’s strategic ambition of getting closer to the patient and end consumer.

The acquisition is designed to create a leading integrated, value-added solutions provider in drug development, formulation, delivery technologies and manufacturing for the global pharma and consumer healthcare industries. The combined business will be well positioned to benefit from the dynamics in these industries and to anticipate and address technology trends in order to support the evolving needs of its customers. It will provide additional value by offering an integrated portfolio of industry-leading technologies, from active pharmaceutical ingredients (APIs) through excipients to dosage forms and delivery technologies.

With the addition of Capsugel’s world-leading advanced oral dosage delivery technologies, including its leading position in hard capsule technologies, Lonza will become the partner of choice for its pharma customers along the entire value chain. The combined technologies and offerings will provide customers innovative solutions in both large and small molecules and solidify Lonza’s position as the partner best able to support the pharma industry by bringing new, differentiated medicines to market rapidly and efficiently.

In addition, the acquisition is expected to strengthen Lonza’s position in consumer healthcare and nutrition as Lonza becomes a fully integrated and innovative service provider of active ingredients, oral dosage forms, development services and delivery technologies. As a result Lonza will be well positioned to meet the increasing need for optimized consumer health and nutrition through a wide offering of next-generation dosage forms. The combined business will also be able to leverage its bioavailability technology to create a new dietary ingredient-ready offering, as well as capitalize on its formulation expertise to develop new ingredients and to market new combination products.

The enlarged business would have had combined 2015 revenues of approximately CHF 4.8 billion and adjusted EBITDA of approximately CHF 1.1 billion with an enhanced margin profile. Lonza and Capsugel’s highly synergistic customer base and complementary business models will facilitate seamless integration. The combined business will be able to leverage the strong regulatory track record and global footprint of each company.

With approximately 3,600 employees and 13 facilities on three continents, Capsugel has a customer-centric, entrepreneurial and collaborative culture that closely aligns with Lonza’s corporate culture. Both companies focus on quality, operational excellence and delivering on promises.

Richard Ridinger, Chief Executive Officer of Lonza, commented, “The acquisition of Capsugel meets Lonza’s strategic and financial goals. It accelerates our healthcare continuum strategy by giving us broader exposure to the fast-growing pharma and consumer healthcare markets. We expect the transaction to be accretive to our core earnings per share in the first full year post closing.”

He explained further, “This new integrated approach will benefit our customers, who will gain from the simplicity and efficiency of working with one company that can provide world-leading support from APIs to excipients and dosage forms. The combined business will allow us to partner with our customers to help them bring highly differentiated products to market more quickly and efficiently.”

Guido Driesen, President and Chief Executive Officer of Capsugel, said, “This transaction brings together two leading companies that share a common vision – to deliver real value to customers by accelerating their ability to develop and commercialize innovative pharmaceutical and healthcare products. The combination of our complementary technology platforms will put us in a strong position to benefit from evolving trends in the pharma and consumer healthcare markets.”

He added, “Both companies enjoy a strong quality and regulatory track record, and we believe that the combination enables us to provide the most complete set of tailored and integrated solutions for our customers. We look forward to bringing together our talented teams to deliver science- and engineering-based solutions to customers for the benefit of the patients and consumers who use their products. I am personally committed to making this integration a success.”

Pete Stavros, Member of KKR and Head of the Industrials Investing Team, said, “Since acquiring Capsugel five years ago, we have supported Guido and his management team in repositioning the company from a global leader in hard capsules into a specialty CDMO. Capsugel has grown significantly by investing in innovation, strategic acquisitions, product development and geographic expansion. Now Capsugel is well positioned for the next phase of its growth, and we look forward to its continued success as a part of Lonza.”


The bulk of the benefits resulting from the transaction will be gained from positive top-line and innovation synergies. The highly synergistic customer base, the expanded addressable market and the improved value proposition for the customer will allow Lonza to further leverage its current product and service offerings. Also the acquisition of Capsugel will allow cross-selling of existing products, combine manufacturing solutions and services and create an integrated value offering that merges Lonza’s ingredients with Capsugel’s dosage forms.

The primary initial focus of this transaction is to ensure a seamless integration while continuing the strong growth trajectory of the Capsugel business. Lonza believes that the step-by-step integration will preserve the strong innovation culture and lead to a combined top-line synergy potential of around CHF 100 million per annum in the mid- to long-term.

Lonza expects to achieve operating synergies of CHF ~30 million per annum, which are expected to be fully realized by year three, in the areas of corporate, procurement and IT, as well as various efficiency gains. In addition, tax synergies of CHF ~15 million per annum are expected.

Lonza anticipates that the transaction will be accretive to its CORE Earnings per Share (EPS) from the first full year post closing onwards and intends to retain its current dividend policy.

Financing and Approvals

The USD 5.5 billion all-cash acquisition of Capsugel will be financed with a combination of debt and equity financing. Lonza has committed debt financing for the full acquisition amount from BofA Merrill Lynch and UBS and plans to raise equity, which is fully underwritten by UBS and BofA Merrill Lynch for an amount up to CHF 3.3 billion.

Lonza’s Board of Directors is currently authorized to increase the share capital through the issuance of 5,000,000 fully paid-in registered shares. Lonza’s Board intends to seek approval for additional share capital at its upcoming annual general meeting (AGM) in April 2017.

Lonza expects to retain a leverage profile around ~3x net debt/EBITDA at closing and to maintain its unofficial investment-grade credit profile assigned by a number of Swiss banks. Lonza believes that the strong projected cash flow of the combined company will enable rapid de-leveraging after the acquisition and continue to support all planned growth initiatives.

The financial package foresees the refinancing of Lonza’s current CHF 700 million revolving credit facility.

The transaction is expected to close in the second quarter of 2017 and is subject to certain regulatory approvals and other customary closing conditions.

Additional information about Lonza can be found on www.lonza.com, about Capsugel on www.capsugel.com, and about the acquisition on the dedicated transaction website www.TheFutureLonza.com, which may be updated from time to time.

Jefferies LLC is serving as lead financial adviser to Lonza. UBS AG and BofA Merrill Lynch also provided financial advice. Jenner & Block LLP is serving as Lonza’s legal counsel. Goldman Sachs is serving as sole financial adviser to Capsugel. Simpson Thacher & Bartlett LLP is serving as Capsugel’s legal counsel.

About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients.

Further information can be found at www.lonza.com.

Lonza Contact Information

Categories: News


Mitsui to Join KKR and Panasonic as an Investor in Panasonic Healthcare

Mitsui & Co

TOKYO– Mitsui & Co., Ltd. (“Mitsui”), one of Japan’s largest diversified corporations, and global investment firm KKR today announced the signing of a definitive share purchase agreement for Panasonic Healthcare Holdings (“PHCHD” or “Panasonic Healthcare”), a global provider of healthcare devices. Under the agreement, Mitsui will acquire a 22% stake in PHCHD for JPY54.1 billion (US$510 million).

Mitsui will acquire its shares from KKR, which invested in PHCHD in 2014 from its pan-regional Asian Fund II. Following the completion of this transaction, KKR will own approximately 58% of PHCHD, Mitsui approximately 22%, and Panasonic Corporation approximately 20%.

PHCHD develops, manufactures, and sells healthcare devices, focusing on blood glucose monitoring systems and strips for people with diabetes through its subsidiary Panasonic Healthcare Co., Ltd. In January 2016, PHCHD acquired Ascensia Diabetes Care (“Ascensia”), formerly the diabetes care unit of Bayer Aktiengesellschaft, a leading provider of diabetes care solutions to people with diabetes and healthcare professionals in 125 countries around the world.

Hidehito Kotani, President of PHCHD, said, “Panasonic Healthcare strives to be a global provider of innovative and customer-centric healthcare devices to help and serve our customers and contribute to the well-being of society. We believe that Mitsui’s expertise, experience and networks in the healthcare business, especially in Asia, will help us grow further and compete globally. We welcome Mitsui as a shareholder that will help us in achieving our aims.”

PHCHD’s mission is to provide innovative technologies and accessible health care solutions to patients worldwide. The Company continually strengthens its focus on providing high-quality and life-enhancing products to diabetes patients globally given the growing incidence of the disease. According to the International Diabetes Federation, the number of people living with diabetes is expected to increase from 420 million in 2015 to 640 million people in 2040, and an estimated 60% of these people will live in emerging Asian countries.

Hiro Hirano, Member & CEO of KKR Japan, said, “Since 2014, we have worked closely with Panasonic Healthcare’s strong management team to grow the company and capture new opportunities at home and across borders. There is still much that can be done, and we will continue to support the company’s long-term growth. The partnership with Mitsui will greatly enhance the global opportunities for PHCHD.”

Koji Nagatomi, Chief Operating Officer of Mitsui’s Healthcare & Service Business Unit, said, “PHCHD manufactures and sells blood glucose monitoring systems and other healthcare devices globally, and has expanded its business operations as one of the world’s leading manufacturers of medical equipment. By leveraging Mitsui’s network of Asian healthcare organizations, we are confident of contributing to accelerating PHCHD’s growth in collaboration with KKR and Panasonic. We believe that this initiative will also contribute to the creation of service structures that will enhance the convenience of treatment for diabetes sufferers.”

The medical and health care industry has been a key focus area for Mitsui, which has been actively investing in hospital and ancillary businesses in Asia. Through this investment in PHCHD, Mitsui will be able to collaborate with its existing investments in medical institutions and its overseas customer base to promote and support the sale of PHCHD’s medical devices and to strengthen the ability of medical institutions to attract patients. In the emerging markets of Asia, Mitsui aims to build a diabetes treatment service network matched to occurrence of the disease, establishing an easy-to-use ecosystem for patients.

KKR has been investing in Japan through its pan-regional private equity funds since 2010. Japan has been and continues to be a key focus for KKR in the region. To date, KKR has completed three acquisitions in the market: Intelligence Ltd., a leading human resources services company; PHCHD, the carve-out health care business of Panasonic Corporation; and Pioneer DJ, the carve-out DJ equipment business of Pioneer Corporation.

The transaction is subject to customary approvals.

About Panasonic Healthcare Holdings Co., Ltd.
Incorporated in 2014, Panasonic Healthcare Holdings Co., Ltd. (shareholder structure: KKR 80%; Panasonic Corporation 20%) is involved in developing, manufacturing, selling and servicing medical equipment and solutions through its subsidiaries Panasonic Healthcare Co., Ltd. and Ascensia Diabetes Care Holdings Co., Ltd. It seeks to strengthen its three core businesses for In Vitro diagnostics devices, Medical IT and Laboratory and Medical Support devices to contribute to the wellbeing of society by creating new value propositions for all the people who wish for better health. For further information on Panasonic Healthcare Holdings, please visit http://www.panasonic-healthcare.com/global/phchd/.

President: Hidehito Kotani
Headquarters: Minato-ku, Tokyo, Japan
Incorporation: 2014

About KKR
KKR is a leading global investment firm that manages investments across multiple asset classes including private equity, energy, infrastructure, real estate, credit and hedge funds. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world‐class people, and driving growth and value creation at the asset level. KKR invests its own capital alongside its partners’ capital and brings opportunities to others through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. L.P. (NYSE:KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

Categories: News


IK Investment Partners to acquire ZytoService


IK Investment Partners (“IK”) is pleased to announce that the IK VIII Fund has reached an agreement to acquire ZytoService Group (“ZytoService” or “the Company”), a leading compounder of pharmaceuticals for patient-individualised infusions, from the founders and Capiton. Financial terms of the transaction are not disclosed.

Founded in 2002, ZytoService is one of the largest industrially organised §13 AMG (‘Arzneimittelgesetz’) certified compounders for patient-individualised infusions applied mainly in oncology treatment in Germany. The Company is based in Hamburg, where it runs a state-of-the-art compounding facility.

“We are delighted to be working with IK going forward. ZytoService operates in an industry in which IK has extensive expertise, and with their support we will be well placed to further expand our competence and provide the best service to our customers,” said Enno Scheel, Co-Founder of ZytoService.

“We firmly believe in the strengths of partnering with IK. Together, we will continue investing in the business to better address the growing demands of the German healthcare market,” added Thomas Boner, Co-Founder of ZytoService.

Mr Enno Scheel and Mr Thomas Boner, Co-Founders and Co-CEOs of ZytoService will remain with the business in managerial roles, and will be shareholders alongside IK.

“Thanks to IK’s experience in the relevant sector, we quickly recognised ZytoService’s potential. We look forward to backing the management team and expanding the Company’s operational capabilities. We believe ZytoService is ideally positioned to develop further and provide highest quality services to its customers,” said Detlef Dinsel, Managing Partner at IK and advisor to the IK VIII Fund.

Completion of the transaction is subject to custom legal and regulatory approvals.

ZytoService will be the second investment of the 2016 established IK VIII Fund.

Categories: News


Ratos AB: TFS acquires dermatology specialist SCIderm


Ratos’s subsidiary TFS is strengthening its market position in Germany through the acquisition of German dermatology specialist SCIderm GmbH, an industry leader in scientific- and medical consulting and trial execution of dermatology studies.

TFS, an international service provider, a so-called clinical Contract Research Organisation (CRO), which conducts clinical trials for pharmaceutical, biotechnology and medical device companies, is strengthening its market position in Germany through the acquisition of SCIderm. The acquisition enables TFS, who have held a strategic partnership with SCIderm since 2014, to fully leverage on the growing industry demands in dermatology research and integrate SCIderm to its newly established dermatology service division. The combined companies will have approximately 100 employees in Germany and will operate from offices in Hamburg and Munich. SCIderm’s service sales for 2015 amounted to approximately EUR 3,5m.

“TFS acquisition of SCIderm will significantly increase our presence in Germany, a market in which we see a strong potential going forward and where we would look to expand our operations further. SCIderm’s unique dermatology expertise, access to patients and scientific approach to clinical programs will leverage on TFS global capabilities and strong executional infrastructure in conducting global pre- and post-approval trials. There is a distinct consolidation trend in the industry, the acquisition of SCIderm being a proof of that and a part of our growth strategy,” says Dr. Montse Barceló, COO at TFS.

The acquisition is subject to approval by the relevant authorities and is expected to be completed during the fourth quarter.

Ratos invested in TFS in 2015 with a holding of 60%. TFS has approximately 700 employees and reported service sales of EUR 52,9m and EBITDA EUR 5,1m in 2015.

For further information, please contact:
Elin Ljung, Head of Corporate Communications, +46 8 700 17 20
Dr. Montse Barceló, COO at TFS, +34 647 409 222

Categories: News


CFO Martin Öhman has left the Handicare Group


As part of a huge cost saving and downsizing operation there has been decided to outsource the Kista finance function to a UK shared service center. This has made the position of Mr. Öhman redundant. He was CFO of the business unit Patient Handling.

With the recent purchase of Prism Medical ltd. Handicare seems to concentrate their business on the USA and UK market only. Also the bookkeeping of the Dutch subsidiary Bathroom Safety has been closed from October. Most of finance in Heerhugowaard (Handicare Stairlifts) has also been moved to the UK already.

The Swedish Handicare Group is suffering in a highly competence healthcare market.
Last year the company already divested 60% of the business with the sale of Handicare Mobility to Sunrise Medical.
The company is currently owned by private equity company Nordic Capital.

Categories: Personalia


Handicare acquires Prism Medical Ltd.

No Comments



Kista, Sweden (September 1, 2016) Handicare announced today the acquisition of Prism Medical Ltd – a successful patient handling company in North America located in Toronto, Canada and St. Louis, USA. Prism Medical has a proven track record of profitable growth and is a significant player in the Ceiling Lift and Patient Handling market in North America.

Prism Medical’s revenue for 2016 will be in the range of 50M USD with 250 people employed. The new combined product portfolio and sales network will put Handicare in a top tier position in North America. The combined product portfolio will later in 2016 be available to both Prism Medical’s and Handicare’s customers worldwide. Moreover, Prism Medical dealers in North America will now have access to Handicare’s stairlifts product range.

Charley Wallace will assume the role as President & CEO of Handicare North America and Ross Scavuzzo will continue to lead in Canada, as President of Handicare Canada.

Asbjörn Eskild, CEO of Handicare Group, says: “We have for a period searched for a company that can support Handicare’s growth strategy in North America. A healthy company that also shares our values and puts the customer and patient in focus. Prism Medical is a perfect match to us”.

Prism Medical manufactures a broad range of high-quality products, including fixed ceiling lifts, portable ceiling lifts, floor lifts, slings, and other ancillary patient handling products, and provides related sales, installation, training and maintenance services through a combination of direct sales, regional sales and service centres, and independent dealers. Prism Medical also sources and distributes third party products such as stairlifts, baths, and beds to customers in each market that it serves, to provide a complete service solution and leverage the company’s well-established distribution channels.


Handicare was founded in 1986 and supplies technical aids for the elderly and physically disabled. Its products include stairlifts, transfer and lifting products, automobile adaptation solutions and homecare products. Handicare’s brand products are distributed through a comprehensive network of professional dealers and distributors in 30 countries around the world. Through its subsidiary Puls, the group is also a market leader in the sale of capital goods and consumables to hospitals and institutions in Norway. Handicare has 950 employees and its headquarters in Kista, Sweden, and has subsidiaries in Norway, Denmark, Germany, the Netherlands, England, Belgium, France, and the US. For more information, please see www.handicare.com.


Prism Medical is a vertically integrated manufacturer and leading provider of equipment and services used to move and handle mobility challenged individuals in a safe and dignified manner. Prism Medical’s products are marketed under the brand names of Prism Medical, ErgoSafe, Waverley Glen and Nightingale in the homecare, acute care and long-term care markets throughout North America. Prism Medical offers solutions that encourage improved care, quality of life and mobility, while seeking to lower the overall cost of the caregiving function in a number of ways, including reducing the incidence of handling-related injuries among caregivers. Through its network of dealers, Prism Medical provides an integrated suite of products and services that make homecare a viable option for many people. For further information visit Prism Medical’s website at www.prismmedicalltd.com or www.sedar.com.

Categories: News


Canadian medical technology company LABORIE to become new subsidiary


Patricia Industries, a part of Investor AB, has signed an agreement with Audax Private Equity to acquire the Canadian medical technology company LABORIE, which focuses on the diagnosis and treatment of urologic and gastrointestinal disorders that affect the daily lives of millions. LABORIE was founded in 1967 and has grown organically and through acquisitions from a leading manufacturer of capital equipment for urodynamic testing into a fully-integrated medical device company with a market-leading position in urology and a rapidly growing gastroenterology business. LABORIE has an attractive, asset-light business model with a high share of its revenue derived from recurring sales of proprietary consumables. LABORIE’s global manufacturing, development and commercialization capabilities create a solid platform for growth through organic and non-organic expansion in core and adjacent markets, new geographies and further expansion beyond diagnostics into therapeutic products. LABORIE will continue to be run by its current management team, which will remain part-owners of the company.

LABORIE will be the most recent addition to the Patricia Industries portfolio of high-quality growth companies, whose other healthcare holdings include Mölnlycke Health Care, Permobil, Aleris and BraunAbility.

Categories: News


Press Ganey enters into Definitive Agreement to be Acquired by EQT

No Comments


Boston, MA, August 9, 2016 – Press Ganey (NYSE: PGND), a healthcare performance improvement company, announced that it has entered into a definitive agreement to be acquired by EQT Equity fund EQT VII (“EQT”), part of the global private equity group EQT. Under the terms of the agreement, EQT will acquire all of Press Ganey’s common stock. Shareholders of record will receive $40.50 in cash per share of Press Ganey common stock, resulting in an enterprise value of approximately $2.35 billion. The offer price represents a 20% premium to the year to date volume-weighted average price and a 62% premium to the initial public offering price for the common stock. The acquisition of Press Ganey represents EQT’s first direct EQT Equity investment in North America.

Categories: News


Sunrise Medical acquires Handicare’s Mobility Business

Sunrise Medical announced today the acquisition of Handicare’s Mobility division‎, headquartered in Helmond, the Netherlands. This follows the acquisition of Sunrise Medical by Nordic Capital that was announced in June 2015.

The Handicare product lines that form part of this acquisition are limited to mobility products such as wheelchairs, scooters and rollators. All other Handicare product lines such as Accessibility, Patient Handling, car adaptations etc. are not part of this transaction.

Handicare’s Mobility business with divisions in Norway, Sweden, Denmark, Holland, Belgium, Germany, France and Canada, will expand Sunrise`s geographic and product reach. Sunrise Medical’s annual sales post transaction will well exceed €400m, cementing their leadership position as the single biggest Premium Mobility Company globally.

Thomas Rossnagel, President and CEO of Sunrise Medical, is excited by the opportunity that this acquisition presents, “Sunrise Medical has seen very strong growth over the past ‎five years, organically and by way of strategically important and successful acquisitions. To now acquire Handicare’s Mobility business makes perfect commercial sense. This business is highly complementary to Sunrise Medical’s, geographically as well as from a product perspective”.

Johan Ek, Handicare’s Chairman and acting CEO, added: “Sunrise Medical is the perfect home for continued successful development of our mobility business. Handicare Group will now have the opportunity to further focus on investing and growing our remaining business segments.”

Sunrise Medical’s intention is to integrate Handicare’s Mobility business over the course of the next 12-18 months. To facilitate a smooth transition, a brand license agreement has been signed allowing Sunrise Medical to continue to use the Handicare brand/logos for their mobility product lines for an agreed period of time. All other product related brands, name rights and all Intellectual Property rights relating to Handicare Mobility`s products will transfer to Sunrise Medical upon closing of the deal which is expected to take place by the end of September 2015.

Categories: News